INTRAVESICAL INTERLEUKIN-2 IN T1 PAPILLARY BLADDER CARCINOMA: REGRESSION OF MARKER LESION IN 8 OF 10 PATIENTS-Reference-Cited by-同舟云学术

INTRAVESICAL INTERLEUKIN-2 IN T1 PAPILLARY BLADDER CARCINOMA: REGRESSION OF MARKER LESION IN 8 OF 10 PATIENTS

Published:1998-04 Issue:4 Volume:159 Page:1183-1186
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

DEN OTTER WILLEM¹,DOBROWOLSKI ZYGMUNT¹,BUGAJSKI ANDREJ¹,PAPLA BOLESLAW¹,VAN DER MEIJDEN A.P.M.¹,KOTEN JAN W.¹,BOON TOM A.¹,SIEDLAR MACIEJ¹,ZEMBALA MAREK¹

Affiliation:

1. Department of Functional Morphology, Utrecht University and Departments of Urology, University Hospital Utrecht, Utrecht and Groot Ziekengasthuis, 's-Hertogenbosch, The Netherlands, and Departments of Urology (Clinic of Urology), Pathology and Clinical Immunology, Jagiellonian University Medical College, Cracow, Poland.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma;Den Otter;Anticancer Res.,1993

2. Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up;Den Otter;Cancer Immunol. Immunother.,1995

3. Optimal regimes for local IL-2 tumour therapy;Den Otter;Int. J. Cancer,1996

4. Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma;Hill;Vet. Immunol. Immunopathol.,1994

5. Intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer: results after 15 years of experience;Van der Meijden;Anticancer Res.,1991

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The past, present, and future of immunotherapy for bladder tumors;Medical Oncology;2022-09-29

2. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo;Journal for ImmunoTherapy of Cancer;2020-12

3. The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery;Life;2020-10-05

4. Elucidating the Immune-Related Mechanisms by Which Probiotic Strain Lactobacillus casei BL23 Displays Anti-tumoral Properties;Frontiers in Microbiology;2019-01-11

5. Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial;Urologia Internationalis;2018-09-28